Funding
FY2024 second MU-TECH research grant · Biotech

Revascular Bio wins JPY3m grant for haemophilia cell therapy

The MU-TECH award supports research using vascular endothelial stem cells.

By RoundOS Funding desk

Revascular Bio Co., Ltd. has won a JPY3 million MU-TECH research grant, announced on February 17, 2025. The selected project develops an endothelial stem-cell approach to haemophilia treatment.

The Osaka University startup is investigating how cells that maintain blood vessels could become therapeutic products. Its research includes difficult-to-treat skin ulcers and diseases involving defective protein production.

Use of funds

Develop endothelial stem-cell therapy for haemophilia

Funding history

FY2024 second MU-TECH research grant · This round¥3M
AMED drug-discovery ecosystem grantUndisclosedOUVC2 investment¥220M

Sources

  1. MU-TECH FY2024 second research grant awardsmutech.or.jp · Feb 17, 2025
  2. MU-TECH FY2024 annualmutech.or.jp
  3. revascularbio.com

Similar rounds

All Biotech rounds →
ALLOX

ALLOX combines high-throughput genetics, experimental biology and AI to find functional sites on proteins and develop targeted small-molecule medicines.

$10.5MSeed · Oct 29, 2026
Dren Bio

Dren Bio develops antibody therapies for cancer, autoimmune conditions and other serious diseases.

$350MPrivate financing · Oct 29, 2026
BioGeometry

BioGeometry develops generative AI models and experimental workflows for protein design, drug discovery and enzyme engineering.

UndisclosedSeries A+ · Oct 28, 2026
IntegriCulture

IntegriCulture develops cell-culture systems and production technology for cellular foods, cosmetics and other biological materials.

UndisclosedFunding round · Oct 28, 2026

Related